FutureBrain

What is FutureBrain?

FutureBrain is a research and development venture implemented and coordinated by a passionate of neuroscience working together with an equally passionate of business, administration, and legal professional. We are brought together, not only by a passion for what we do and what we would like to accomplish together but also by a lofty mission.

A mission to realize innovative ideas and concepts that will:

• revolutionize the existing field of neuropsychiatry,
• bring it to a new medical and technological level that was previously impossible,
• give impetus to doctors and scientists around the world in areas of the field that are still unknown or poorly understood, and
• simplify public and private neuropsychiatric care, leading to a significant reduction in the costs associated with it.

Above all, we aim to positively affect the treatment and care of millions of people around the world struggling with neuropsychiatric problems. Put simply, our goal is to make life easier for all of us.

Vision for the Future

Looking to the future, we will also launch a commercial venture which offers interested business entities specific solutions and products that were created as a result of our ongoing research and development–including the use of artificial intelligence and innovative digital health solutions. This will provide patients with modern, low-cost, and fast diagnosis as well as the comprehensive treatment of neuropsychiatric disorders, especially within the framework of our own medical clinic.

If this sounds good to you, then let’s get started! Vision is not everything, it’s the result that counts and we know how to achieve it.

PhD. Paweł Wańkowicz Neurologist/Neuroimmunologist

Research Topics

1. Primary prevention of ischemic stroke associated with atrial fibrillation– is oral anticoagulant therapy sufficient?

The following scientific articles have been written based on the research conducted within the framework of this research with his leading participation:

• Wańkowicz P., et al. Risk factors for ischemic stroke in patients with non-valvular atrial fibrillation and therapeutic international normalized ratio range. Arch Med Sci. 2019 Sep;15(5):1217-1222.
• Wańkowicz P., et al. Atrial fibrillation risk factors in patients with ischemic stroke. Archives of Medical Science. 2021;17(1):19-24.
• Wańkowicz, P., et al. Ischemic Stroke Risk Factors in Patients with Atrial Fibrillation Treated with New Oral Anticoagulants. J. Clin. Med. 2021, 10, 1223. 
• Wańkowicz P., et al. Pre-Stroke Statin Therapy Improves In- Hospital Prognosis Following Acute Ischemic Stroke Associated with Well-Controlled Nonvalvular Atrial Fibrillation. J Clin Med. 2021;10(14):3036.

• Research on neuropsychiatric disorders in systemic lupus erythematosus

This research has become the subject of the following publications:

• Wańkowicz P., et al. Clinical manifestations of neuropsychiatric systemic lupus erythematosus: a single-center study from West Pomerania Province in Poland. Pol Arch Intern Med. 2020;130(1):82-84. 
• Wańkowicz P., et al. An overlapping case of Bickerstaff brainstem encephalitis and acute motor axonal neuropathy variant of Guillain-Barré syndrome associated with systemic lupus erythematosus. Pol Arch Intern Med. 2019, Jan 31;129(1):50-51.
  • This publication is based on the case of a young patient with a diagnosis of systemic lupus erythematosus, who was additionally diagnosed by Dr. Wańkowicz with a syndrome of overlapping Bickerstaff’s truncus inflammation and acute axonal motor neuropathy, which is a variant of Guillain-Barre syndrome. Prior to receiving care, the patient’s general and neurological condition had steadily deteriorated. After the above variant was diagnosed and appropriate treatment was administered, the patient’s general and neurological condition improved from week to week.

• Mental health in the era of the COVID-19 pandemic

Current research in the era of COVID-19 deals only marginally with the role of autoimmune diseases as a major trigger or exacerbator of mental disorders or insomnia during the COVID-19 pandemic. Three of the current studies relating to this issue were conducted by Dr. Paweł Wańkowicz’s team. They were the basis for the following publications:

• Wańkowicz, P., et al. Assessment of Mental Health Factors among Health Professionals Depending on Their Contact with COVID-19 Patients. Int. J. Environ. Res. Public Health 2020, 17, 5849.
• Wańkowicz, P., et al. Evaluation of Mental Health Factors among People with Systemic Lupus Erythematosus during the SARS-CoV-2 Pandemic. J.Clin. Med. 2020, 9, 2872.
• Wańkowicz, P., et al. The Impact of the COVID-19 Pandemic on Psychological Health and Insomnia among People with Chronic Diseases. J. Clin. Med. 2021, 10, 1206.
• Wańkowicz, P., et al. Insomnia, Anxiety, and Depression Symptoms during the COVID-19 Pandemic May Depend on the Pre-Existent Health Status Rather than the Profession. Brain Sci. 2021, 11, 1001.

Innovation Incubator 2.0 Project

Creating a test for the neuropsychiatric form of systemic lupus erythematosus. Can we predict the future?

Given Dr. Paweł Wańkowicz’s long-standing observation of patients with autoimmune diseases, in 2017-2018 he conducted an interdisciplinary pilot study to compare the concentration of factors that influenced neuroimmune response in patients with the neuropsychiatric form of systemic lupus erythematosus and healthy volunteers. The study results became the basis for the winning of a grant in the Innovation Incubator 2.0 competition in 2019. The project is currently in the commercialization phase.

The implementation of the Innovation Incubator 2.0 project has paid off through expanded international collaborations. Since 2018, Dr. Paweł Wańkowicz has been collaborating with the Universidad Catolica San Antonio de Murcia in Spain in the field of autoimmune disease research, and, in particular, in the study of the neuropsychiatric form of systemic lupus erythematosus.

Marcin Narloch

He has been successfully advising foreign and Polish companies in establishing, organizing, conducting, and developing business activities in Poland for more than 19 years. He supports his clients with his knowledge, extensive experience, creative ideas, and innovative legal solutions.

In 2015, he became the managing partner of a law firm, where he provided his services as a legal advisor.

In the 21st century, current medicine and the entire world’s concerns revolve around oncology and cardiovascular disease. It is in this field that the most intensive, multidirectional research is being conducted. However, according to recent reports, autoimmune diseases are becoming as common as cardiovascular and cancer diseases. For many scientists, these disorders rank third on the list of the most prevalent chronic diseases in the world. There are some scientists who proclaim that the number of patients suffering from autoimmune conditions exceeds the total number of oncology and cardiology patients.

Neuroimmune disorders, on the other hand, are currently practically invisible due to the following issues:

• Today’s neuropsychiatry bases its conclusions and diagnoses mainly on achievements dating back to the time of Carl Benz’s first car, i.e. the late 19th century.
• There is a lack of interdisciplinary specialists who are able to comprehensively and professionally deal with this field of medicine–not only in Poland but all over the world.
• Including Dr. Paweł Wańkowicz there are only a few doctors globally specializing in neuroimmunology.
• It is not even considered a medical specialization in Poland.
• Many specialists downplay symptoms that may suggest neuropsychiatric disorders.

The current global market does not address the problem of neuropsychiatric disorders. From a neurologist’s point of view, the only actual diseases are ischemic stroke, multiple sclerosis, epilepsy, and Parkinson’s disease.

Our research is directed toward the practical application of knowledge about diseases, such as multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, and the whole range of neuropsychiatric conditions coupled with the continued further development of the knowledge in question.

In this way, our research and the knowledge gained from it will contribute to the further development of new diagnostic methods using artificial intelligence and modern, targeted pharmacological treatment of patients with neuropsychiatric conditions.

The main goal of our research is to create methods, solutions, and specific innovative products that will positively affect diagnoses, their speed, and in the long run the treatment of the entire population of patients struggling with neuropsychiatric disorders.

It is important to note that there is a part of the world’s population that does not even know that they have these disorders, while others remain under observation because they have not yet met all the criteria necessary for diagnosis and the implementation of treatment.

This is a troublesome situation that requires immediate change.

Like any venture, our project is based on an action plan prepared in advance. The creation of the FutureBrain startup is phase one of our plan. It is based on four pillars:

1. Knowledge and Ideas     

We have many years of expertise gained through the following medical and scientific activities:

• observation of patients,
• intensive cooperation in research projects and their management,
• scientific conferences,
• networking with other specialists, and
• current analysis of the medical market and technological solutions.

This affirms that we have the relevant knowledge to successfully implement all of our theories.

This knowledge, coupled with our creativity, has resulted in the birth of new ideas and the development of concepts that we are dedicated to successfully implementing.

In addition to the five points above, we are also backed by professional legal and organizational support–including a patent attorney.

2. Preparation

The preparation of a comprehensive and detailed action plan, combined with our knowledge and ideas, will contribute to our success.

3. Organization

It is also important to remember the efficient and necessary organization of the entire research process, including all of its essential elements.

4. Implementation

Once we are thoroughly prepared and armed with all the necessary tools, we can begin to implement our objectives.

We are not interested in conducting research for many years with no end in sight, without a specific result, simply for the sake of doing it, or with no basis for achieving our goals and ideas.

Our only focus is to achieve our set goals. As we fulfill all the pillars of our action plan we will meet the urgent need for innovative methods, solutions, and products, which will be the result of our research and development activities.

Like any growing startup, we are also open to cooperation with other entrepreneurs, research institutes, academic universities, scientists, specialists, and enthusiasts who are willing to participate in our project.

If you are interested in our field of activity, can envision a future in it, or would like to support us, you are welcome to contact us. Our contact information can be found here.